

CELL THERAPEUTICS INC  
Form 8-K  
April 20, 2012

# **SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

## **FORM 8-K**

### **CURRENT REPORT**

**Pursuant to Section 13 or 15(d) of the  
Securities Exchange Act of 1934**

**Date of Report:**

**April 20, 2012**

**(Date of earliest event reported)**

## **CELL THERAPEUTICS, INC.**

**(Exact name of registrant as specified in its charter)**

Edgar Filing: CELL THERAPEUTICS INC - Form 8-K

**Washington**  
(State or other jurisdiction of  
incorporation or organization)

**001-12465**  
(Commission  
File Number)  
**501 Elliott Avenue West, Suite 400**

**91-1533912**  
(I.R.S. Employer  
Identification Number)

**Seattle, Washington 98119**

**(206) 282-7100**

(Address including zip code, and telephone number, including  
area code, of Registrant's principal executive offices)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

- .. Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- .. Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- .. Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- .. Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

**Item 2.02 Results of Operations and Financial Condition.**

*The information provided pursuant to this Item 2.02 shall not be deemed filed for purposes of Section 18 of the Securities Exchange Act of 1934 (the Exchange Act), or otherwise subject to the liabilities of that section, and shall not be incorporated by reference into any filing or other document filed by the Company pursuant to the Exchange Act or the Securities Act of 1933, as amended (the Securities Act), except as shall be expressly set forth by specific reference in such filing or document. The information provided pursuant to this Item 2.02 shall instead be deemed furnished.*

On April 20, 2012, Cell Therapeutics, Inc. issued a press release announcing its financial results for the quarter ended March 31, 2012 and certain other information. The full text of the press release is set forth in Exhibit 99.1 hereto.

**Item 9.01 Financial Statements and Exhibits.**

(d) Exhibits.

The following exhibit is furnished with this report on Form 8-K:

Exhibit Number	Description
99.1	Press Release dated April 20, 2012.

**SIGNATURE**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

CELL THERAPEUTICS, INC.

Date: April 20, 2012

By:

/s/ LOUIS A. BIANCO  
**Louis A. Bianco**

**Executive Vice President, Finance and Administration**

-2-

**EXHIBIT INDEX**

Exhibit Number	Description
99.1	Press Release dated April 20, 2012.